New Developments in Research

The Cystic Fibrosis Foundation invests in preclinical and clinical research to develop potential therapies that target cystic fibrosis from all angles. Watch top cystic fibrosis researchers talk about the latest developments.

Preclinical Research and New Technologies

In this video, Michael P. Boyle, M.D., senior vice president of therapeutics development at the Foundation, talks about the latest preclinical research (a stage of research immediately before clinical trials) and why the Foundation is pursuing new technologies, such as gene editing and gene therapy. To learn more, you can visit the Foundation's Drug Development Pipeline, which enables you to track the progress of potential CF therapies as they move from the preclinical stage to each clinical trial phase.

CFTR Modulators

In this video, George M. Solomon, M.D., assistant professor of medicine and director of the adult CF program at the University of Alabama at Birmingham, explains what the cystic fibrosis transmembrane conductance regulator (CFTR) protein does and why correcting and restoring function to the CFTR protein is a central focus of CF research. Dr. Solomon also provides updates on new developments in CFTR modulators, including the triple combination therapies that could help people with CF who have a wider range of CFTR mutations.

Mucociliary Clearance

Scott H. Donaldson, M.D., associate professor of medicine and director of the adult CF center at the University of North Carolina, discusses why people with CF have trouble clearing mucus from their lungs and why this causes problems. He talks about what types of drugs are being developed to improve mucociliary clearance, the process of breaking down and moving mucus out of the lungs.


Deepika Polineni, M.D., M.P.H., assistant professor of internal medicine at the University of Kansas Medical Center and associate adult program director of the University of Kansas CF Care Center, discusses why inflammation is a problem for people with CF and the strategies researchers are using to develop anti-inflammatories.